BQ-3020 (trifluoroacetate salt) |
| Katalog-Nr.GC49885 |
A peptide ETB receptor antagonist
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
BQ-3020 is a peptide endothelin type B (ETB) receptor agonist.1 It selectively binds to ETB over ETA receptors (IC50s = 0.07 and 940 nM, respectively) and induces inositol triphosphate formation and calcium mobilization in isolated bovine carotid artery endothelial cells.1,2 BQ-3020 increases or decreases renal perfusion pressure in Dahl salt-resistant or -sensitive rats, respectively.3 It decreases the production of nitric oxide (NO) and induces vasoconstriction in a rat model of diet-induced hypercholesterolemia.
1.Ihara, M., Saek, T., Fukuroda, T., et al.A novel radioligand [125I]BQ-3020 selective for endothelin (ETB) receptorsLife Sci.51(6)PL47-PL52(1992) 2.Hirata, Y., Emori, T., Eguchi, S., et al.Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cellsJ. Clin. Invest.91(4)1367-1373(1993) 3.Kakoki, M., Hirata, Y., Hayakawa, H., et al.Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidneyCirculation99(9)1242-1248(1999)
Average Rating: 5 (Based on Reviews and 14 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *